Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Baylor Research Institute
Sponsor:
Information provided by (Responsible Party):
Baylor Research Institute
ClinicalTrials.gov Identifier:
NCT01802970
First received: February 28, 2013
Last updated: March 4, 2014
Last verified: March 2014
  Purpose

To determine the safety of administering anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with metastatic breast cancer (MBC), as well as determining blood immune cell transcriptional signatures in patients who undergo IL-1 receptor blockade.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: Anakinra plus Standard of Care
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

Resource links provided by NLM:


Further study details as provided by Baylor Research Institute:

Primary Outcome Measures:
  • Safety - Adverse Events in participants [ Time Frame: up to 7 months ] [ Designated as safety issue: Yes ]
    Patients will receive anakinra plus the physicians chemotherapy choice of nab paclitaxel, or capecitabine, or eribulin, or vinorelbine for metastatic breast cancer. Adverse events will be recorded throughout the trial, and regardless of the severity will be followed up by investigator until resolution is satisfactory. All adverse events and toxicities will be recorded and assessed for 30 days following the last dose of anakinra at a maximum of 6 months. Grading will be done using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.


Secondary Outcome Measures:
  • To determine investigator-assessed objective response rate, clinical benefit rate, progression-free survival, and rates of chemotherapy or cancer-related anemia (HgB<10), and an anakinra-induced anti-IL-1 blood transcriptional signatures [ Time Frame: upto 7 months ] [ Designated as safety issue: No ]
    Objective response rate, clinical benefit rate and progression-free survival in patients will be determined using radiological assessment of tumors (CT/MRI/X-ray/PET), clinical and functional evaluation of patients with 95% confidence intervals. Whole blood transcriptional profiling will be performed to determine a gene expression signature that is induced by IL-1 receptor blockade by anakinra. The gene expression signatures from baseline will be compared to those signatures obtained after the 2-week run-in treatment with anakinra alone. During the treatment, complete blood count with differential/platelet count and complete metabolic profiling will be done to identify any baseline changes.


Estimated Enrollment: 20
Study Start Date: December 2012
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anakinra plus Standard of Care
Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
Drug: Anakinra plus Standard of Care
Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
Other Names:
  • Anakinra: kineret
  • Nab paclitaxel: Abraxane
  • Capecitabine: Xeloda
  • Eribulin: Halaven
  • Vinorelbine: Navelbine

Detailed Description:

In an attempt to reverse the immune suppressive microenvironment and to enhance chemotherapy effectiveness, decrease tumor metagenicity and decrease IL-1-induced fatigue, metastatic breast cancer (MBC) patients will be treated with chemotherapy plus anakinra. This is a pilot safety, single arm, open label trial. The objective is to determine the safety of anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with MBC and to define an anakinra-induced anti-IL-1 whole blood transcriptional profile.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female or male patients ≥18 years of age.
  • Histologically confirmed invasive breast cancer, locally unresectable or metastatic.
  • No more than 2 prior chemotherapy regimens for metastatic disease.
  • Patients currently being treated with nab paclitaxel, capecitabine,eribulin, or vinorelbine who have had a CR, PR, or SD and who have developed Grade 2, 3, or 4 fatigue on the chemotherapy are eligible for the study. It should be anticipated that these patients will continue to be treated on the same chemotherapy agent for at least 3 more months beyond the time of enrollment.
  • Prior hormonal therapy in the adjuvant or metastatic setting is permitted.
  • HER2-negative breast cancer. If HER2-, it is defined as follows:

    1. FISH-negative (FISH ratio <2.0), or
    2. IHC 0-1+, or
    3. IHC 2+ AND FISH-negative (FISH ratio<2.0)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
  • Adequate hematologic function, defined by:

    1. Absolute neutrophil count (ANC) >1500/mm^3
    2. Platelet count ≥100,000/mm^3
    3. Hemoglobin >8 g/dL
  • Adequate liver function, defined by:

    1. AST and ALT ≤2.5 x the upper limit of normal (ULN) or ≤5 x ULN in presence of liver metastases
    2. Total bilirubin ≤1.5 x ULN
  • Adequate renal function, defined by:

    a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥40 ml/min

  • Measurable or nonmeasurable disease by RECIST v1.1 criteria
  • Life expectancy ≥24 weeks
  • Adequate recovery from recent surgery

    1. Major surgical procedure >28 days from study entry
    2. Minor surgical procedure >7 days from study entry (Portacath placement accepted - patients can start treatment <7 days after portacath placement.)
  • Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.
  • Patient must be accessible for treatment and follow-up.
  • All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry

Exclusion Criteria:

  • Patients with active or untreated brain metastases or meningeal metastases are ineligible. Patients who have had brain metastases resected, or have received brain radiation therapy >4 weeks prior to study entry are eligible if they meet all of the following criteria: 1) patient has been off dexamethasone for >2 weeks; 2) no known progression of brain metastasis.
  • Previous radiotherapy for metastatic disease completed <2 weeks prior to study treatment initiation.
  • Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as: -

    1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
    2. uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
    3. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
  • History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or that might affect interpretation of the results of this study, or render the subject at high risk for treatment complications.
  • Patients may not receive any other investigational treatments while participating in this study.
  • Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
  • Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01802970

Contacts
Contact: Grace Townsend 214-818-8382 grace.townsend@baylorhealth.edu
Contact: Silviya Meletath 214-820-4987 silviya.meletath@baylorhealth.edu

Locations
United States, Texas
Baylor University Medical Center Recruiting
Dallas, Texas, United States, 75246
Contact: Grace Townsend    214-818-8382    grace.townsend@baylorhealth.edu   
Contact: Silviya Meletath    214-820-4987    silviya.meletath@baylorhealth.edu   
Principal Investigator: Joyce O'Shaughnessy, MD         
Sub-Investigator: Karolina Palucka, MD, PhD         
Sponsors and Collaborators
Baylor Research Institute
Investigators
Principal Investigator: Joyce O'Shaughnessy, MD Baylor Health Care System
  More Information

No publications provided

Responsible Party: Baylor Research Institute
ClinicalTrials.gov Identifier: NCT01802970     History of Changes
Other Study ID Numbers: 012-099
Study First Received: February 28, 2013
Last Updated: March 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Baylor Research Institute:
Anakinra
Nab Paclitaxel
Capecitabine
Eribulin
Vinorelbin

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Vinorelbine
Paclitaxel
Capecitabine
Interleukin 1 Receptor Antagonist Protein
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents
Antimetabolites, Antineoplastic
Antimetabolites

ClinicalTrials.gov processed this record on August 26, 2014